E. Jabbour and H. Kantarjian, “Chronic Myeloid Leukaemia: 2012 Update of Diagnosis, Monitoring and Management,” American Journal of Hematology, Vol. 87, No. 11, 2012, pp. 1037-1045. doi;10.1002/ajh.23282

has been cited by the following article:

• TITLE: Dasatinib-Induced Hepatic Dysfunction

  AUTHORS: Arumugam Manoharan

  KEYWORDS: Dasatinib; Hepatic Dysfunction; Reversibility

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.4 No.1, January 18, 2013

  ABSTRACT: A 53-year-old man with chronic myeloid leukaemia developed significant hepatic dysfunction when treatment was changed from imatinib (because of drug-induced rash) to dasatinib. Liver function tests returned to normal 77 days after cessation of therapy and have remained normal despite recommencement of dasatinib. Although the pathogenesis for the significant hepatic dysfunction is unclear, this case illustrates the reversibility of this event with dose interruption and that dasatinib can be safely recommenced for ongoing treatment.